Unfortunately, when we designed these trials, my trial as well as a lot of the trials that have been published in Upfront and Advanced and Recurrent and Metasternal Cancer, we lumped all mismatch repair proficient together. And we know that’s not right, right? So we need to break out the HER2 positives, the P53 wild types, the P53 mutants. So with that being said, some of the analyses we previously have done with DuoE have indicated that the potential molecular groups that might benefit the most from the addition of Olaparib are those that with a P53 mutation, BRCA mutation, homologous recombination repair gene mutations...
Unfortunately, when we designed these trials, my trial as well as a lot of the trials that have been published in Upfront and Advanced and Recurrent and Metasternal Cancer, we lumped all mismatch repair proficient together. And we know that’s not right, right? So we need to break out the HER2 positives, the P53 wild types, the P53 mutants. So with that being said, some of the analyses we previously have done with DuoE have indicated that the potential molecular groups that might benefit the most from the addition of Olaparib are those that with a P53 mutation, BRCA mutation, homologous recombination repair gene mutations. But all of that’s exploratory. But certainly that’s the population that I think probably benefits the most from the combination therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.